HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Scope & Guideline

Advancing Insights in Hematology and Oncology

Introduction

Immerse yourself in the scholarly insights of HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0889-8588
PublisherW B SAUNDERS CO-ELSEVIER INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1987 to 2024
AbbreviationHEMATOL ONCOL CLIN N / Hematol. Oncol. Clin. North Am.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899

Aims and Scopes

The journal 'Hematology-Oncology Clinics of North America' aims to provide a comprehensive platform for the latest advancements in hematology and oncology, focusing on the clinical aspects of cancer care and treatment. It encompasses a diverse range of topics that reflect the complexities of cancer treatment and research, with a strong emphasis on multidisciplinary approaches to patient management.
  1. Clinical Innovations in Cancer Treatment:
    The journal features papers on the latest advancements in cancer therapies, including immunotherapy, targeted therapies, and novel drug developments, demonstrating a commitment to improving patient outcomes.
  2. Research on Cancer Pathophysiology:
    It explores the biological mechanisms underlying various cancers, including genetic and molecular studies that inform treatment strategies and improve understanding of disease progression.
  3. Multidisciplinary Management of Cancer:
    The journal emphasizes the importance of collaboration among various specialties in the management of cancer, showcasing studies on surgical, medical, and supportive care approaches.
  4. Health Disparities in Cancer Care:
    There is a focus on addressing inequities in cancer treatment and outcomes, with research highlighting disparities based on socioeconomic status, geography, and access to care.
  5. Preventive Oncology and Early Detection:
    The journal promotes research on cancer prevention strategies, screening methods, and the identification of precursor lesions to facilitate early diagnosis and intervention.
The journal has adapted to the rapidly changing landscape of cancer research and treatment, with several emerging themes gaining traction in recent publications. This section outlines these trending areas that are likely to shape future research and clinical practice.
  1. Advancements in Immunotherapy:
    Recent publications increasingly focus on immunotherapy, particularly CAR T-cell therapy and checkpoint inhibitors, underscoring the shift towards harnessing the immune system to combat cancer.
  2. Targeted Therapies and Precision Medicine:
    There is a prominent trend towards the exploration of targeted therapies tailored to individual genetic profiles, reflecting a growing commitment to precision medicine in oncology.
  3. Biomarkers for Early Detection and Treatment Response:
    Emerging research on biomarkers for cancer detection and monitoring treatment responses is gaining importance, highlighting the need for tools that can guide clinical decision-making.
  4. Global Health and Cancer Disparities:
    The journal is increasingly addressing global health issues in oncology, focusing on disparities in cancer care and treatment outcomes, particularly in low- and middle-income countries.
  5. Integration of Technology in Cancer Care:
    Innovations in technology, such as telemedicine and digital health, are becoming more prevalent in the journal, reflecting the adaptation of cancer care delivery in an evolving healthcare landscape.

Declining or Waning

As the field of oncology evolves, certain themes within 'Hematology-Oncology Clinics of North America' appear to be diminishing in frequency or focus. This section highlights these waning areas, reflecting shifts in research priorities and clinical practice.
  1. Traditional Chemotherapy Approaches:
    With the rise of targeted therapies and immunotherapies, traditional chemotherapy regimens are receiving less emphasis in recent publications, indicating a shift towards more personalized treatment strategies.
  2. Basic Science Research Without Clinical Application:
    There is a noticeable decline in purely basic science research that lacks direct clinical relevance, as the journal increasingly prioritizes studies that translate findings into practical applications in patient care.
  3. Focus on Established Cancer Types:
    Research on well-established cancer types, such as breast and prostate cancer, is becoming less prominent as newer, less common malignancies gain attention, reflecting a broadening scope of interest within the oncology community.

Similar Journals

LANCET ONCOLOGY

Discovering innovative solutions for complex oncology challenges.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Delivering essential insights for the oncology community.
Publisher: OXFORD UNIV PRESSISSN: 0368-2811Frequency: 12 issues/year

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

World Journal of Clinical Oncology

Empowering Oncology with Cutting-Edge Insights
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

INDIAN JOURNAL OF CANCER

Connecting Researchers for a Cancer-Free Future
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0019-509XFrequency: 4 issues/year

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.

Asia-Pacific Journal of Clinical Oncology

Pioneering insights in Asia-Pacific oncology.
Publisher: WILEYISSN: 1743-7555Frequency: 6 issues/year

Asia-Pacific Journal of Clinical Oncology is an essential publication within the field of medical oncology, dedicated to advancing the understanding and treatment of cancer through rigorous research and innovative clinical practices. Published by WILEY, this journal has established itself as a significant resource for researchers, healthcare professionals, and students interested in the latest findings across the Asia-Pacific region and beyond. With a respectable impact factor and categorized within the Q2 and Q3 quartiles of Medicine (miscellaneous) and Oncology respectively, the journal aims to disseminate knowledge on diverse aspects of clinical oncology, promoting the improvement of patient care and treatment outcomes. The Asia-Pacific Journal of Clinical Oncology, operating from the United Kingdom, invites contributions that highlight significant findings and advancements in oncology, making it a crucial platform for collaboration and knowledge sharing in this vital field of medicine.

Cancers

Empowering discovery in oncology and cancer treatment.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

CANCER INVESTIGATION

Illuminating pathways in oncology through peer-reviewed excellence.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

International Journal of Clinical Oncology

Driving Progress in Clinical Practices and Research
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

Clinical Lung Cancer

Elevating standards in oncology and respiratory health.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Frontiers in Oncology

Unlocking the future of cancer care through shared knowledge.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.